
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$19.91
+US$0.26 · +1.32%
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
前收盤價
US$19.91
+US$0.26 · +1.32%
盤中時間採用ET。市場資料可能有所延遲。
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
日內區間
目前US$19.91
52週區間
目前US$19.91
盤中時間採用ET。市場資料可能有所延遲。
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
日內區間
目前US$19.91
52週區間
目前US$19.91
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 30.19億 USD | 27.94億 USD | 23.94億 USD | 22.12億 USD | 20.94億 USD |
| 銷貨成本 | 18.83億 USD | 17.74億 USD | 15.3億 USD | 14.21億 USD | 13.25億 USD |
| 毛利 | 11.36億 USD | 10.2億 USD | 8.64億 USD | 7.91億 USD | 7.69億 USD |
| 研究與開發 | 1.86億 USD | 1.91億 USD | 1.95億 USD | 2.09億 USD | 2.1億 USD |
| 銷售、一般及管理費用 | 5.27億 USD | 4.76億 USD | 4.3億 USD | 4億 USD | 3.66億 USD |
| 營業費用 | 7.13億 USD | 7.71億 USD | 6.59億 USD | 8.86億 USD | 6.16億 USD |
| 利息支出 | 2.41億 USD | 2.59億 USD | 2.11億 USD | 1.58億 USD | 1.36億 USD |
| 折舊和攤銷 | 2.24億 USD | 2.36億 USD | 2.29億 USD | 2.4億 USD | 2.33億 USD |
| 營業利益 | 4.23億 USD | 2.49億 USD | 2.04億 USD | −9492.8萬 USD | 1.53億 USD |
| 淨利 | 7205.7萬 USD | −1.17億 USD | −8399.3萬 USD | −1.3億 USD | 1062.4萬 USD |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$23.20
上漲空間 16.52%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI9742.51萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM8033.12萬0.10%787.4億 USD0.19%US$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB7044.82萬0.04%1853億 USD0.03%US$289.48+0.64%
Dimensional - US Small Cap ETFDFAS4698.67萬0.14%338.69億 USD0.31%US$78.35+0.32%
Vanguard Morningstar Small-Cap Value ETFVBR4479.13萬0.07%682億 USD0.05%US$234.43+0.22%
Invesco S&P SmallCap Momentum ETFXSMO4309.09萬1.50%28.69億 USD0.35%US$81.75+0.57%
Vanguard Extended Market ETFVXF3497.66萬0.04%954億 USD0.05%US$235+0.80%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM3346.68萬0.21%158.4億 USD0.03%US$53.45+0.17%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Morningstar Small-Cap ETFVB
Dimensional - US Small Cap ETFDFAS
Vanguard Morningstar Small-Cap Value ETFVBR
Invesco S&P SmallCap Momentum ETFXSMO
Vanguard Extended Market ETFVXF
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSMAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。